Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials
HPB · 2023
DOI: 10.1016/j.hpb.2023.04.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift HPB, 2023. Verfasst von Quisette P Janssen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: q.janssen@erasmusmc.nl. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
BACKGROUND: Neoadjuvant treatment for pancreatic ductal adenocarcinoma (PDAC) has increased, necessitating histopathologic confirmation of cancer. This study evaluates the performance of endoscopic tissue acquisition (TA) procedures for borderline resectable and resectable PDAC. METHODS: Pathology reports of patients included in two nationwide randomized controlled trials (PREOPANC and PREOPANC-2) were reviewed. The primary outcome was sensitivity for malignancy (SFM), considering both "suspicious for" and "malignant" as positive. Secondary outcomes were rate of adequate sampling (RAS) and diagnoses other than PDAC. RESULTS: Overall, 892 endoscopic procedures were performed in 617 patients, including endoscopic ultrasonography (EUS)-guided TA in 550 (89.1%), endoscopic retrograde cholangiopancreatography (ERCP)-guided brush cytology in 188 (30.5%), and periampullary biopsies in 61 patients (9.9%). The SFM was 85.2% for EUS, 88.2% for repeat EUS, 52.7% for ERCP, and 37.7% for periampullary biopsies. The RAS ranged 94-100%. Diagnoses other than PDAC were other periampullary cancers in 24 (5.4%), premalignant disease in five (1.1%), and pancreatitis in three patients (0.7%). CONCLUSIONS: EUS-guided TA of patients with borderline resectable and resectable PDAC included in RCTs had an SFM above 85% for both first and repeat procedures, meeting international standards. Two percent had false positive result for malignancy and 5% had other (non-PDAC) periampullary cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Electronic address: q.janssen@erasmusmc.nl.
- Department of Gastroenterology, Reinier de Graaf Group, Delft, the Netherlands.
- Department of Surgery, Amsterdam UMC, University of Amsterdam, Cancer Center Amsterdam, Amsterdam, the Netherlands.
- Department of Surgery, Leiden University Medical Center, Leiden, the Netherlands.
- Department of Gastroenterology and Hepatology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
- Department of Pathology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands.
Zitieren
APA
Janssen, Q. P., Quispel, R., Besselink, M. G., Bonsing, B. A., Bruno, M. J., Doukas, M., Sarasqueta, A. F., Homs, M. Y. V., van Hooft, J. E., van Tienhoven, G., van Velthuysen, M. F., Verheij, J., Voermans, R. P., Wilmink, J. W., Groot Koerkamp, B., van Eijck, C. H. J., van Driel, L. M. J. W., & Dutch Pancreatic Cancer Group (2023). Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials. HPB. https://doi.org/10.1016/j.hpb.2023.04.018
Vancouver
Janssen QP, Quispel R, Besselink MG, Bonsing BA, Bruno MJ, Doukas M, et al. Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials. HPB. 2023. doi:10.1016/j.hpb.2023.04.018
BibTeX
@article{Janssen2023,
author = {Janssen, Quisette P and Quispel, Rutger and Besselink, Marc G and Bonsing, Bert A and Bruno, Marco J and Doukas, Michael and Sarasqueta, Arantza F and Homs, Marjolein Y V and van Hooft, Jeanin E and van Tienhoven, Geertjan and van Velthuysen, Marie-Louise F and Verheij, Joanne and Voermans, Rogier P and Wilmink, Johanna W and Groot Koerkamp, Bas and van Eijck, Casper H J and van Driel, Lydi M J W and Dutch Pancreatic Cancer Group, Dutch Pancreatic Cancer Group},
title = {Diagnostic performance of endoscopic tissue acquisition for pancreatic ductal adenocarcinoma in the PREOPANC and PREOPANC-2 trials},
journal = {HPB},
year = {2023},
doi = {10.1016/j.hpb.2023.04.018}
}
EUVIMED